ClinicalTrials.gg
CompletedNCT06188338Updated Aug 16, 2024

A 56-day Clinical Study on Facial Skin Rejuvenation

An interventional study of Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®. and Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002® in Skin Manifestations, Wrinkle and Photoaging, sponsored by Botanee Group Co., Ltd.. Completed at 1 site in China. Open to female participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Botanee Group Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
Female
01

Study summary

This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.

Read the detailed description

The main expectations are:

  • After the 8-week continuous use of the test formulations with MLYAAT-1002® on one split-face side, the clinical manifestations and scores of photoaging improve compared to those of the control side using the placebo formulations.
  • After the 8-week continuous use of the test formulations with MLYAAT-1002®, indicators of skin tone, individual type angle (ITA), CIELAB color space, pores and wrinkles improve compared to those of the control side using the placebo formulations.
02

Conditions studied

  • Skin Manifestations
  • Wrinkle
  • Photoaging

Browse trials for

03

In context

Skin Manifestations

29 studies on the registry are indexed under Skin Manifestations; 5 are open to participants now.

This study's enrollment of 24 is below the median of 75 across 23 interventional studies indexed under Skin Manifestations.

Browse Skin Manifestations studies →

Lead sponsor

Botanee Group Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • self-reported facial aging problems such as roughness, fine lines, and dull skin
  • no symptoms of itching, tingling, or burning on the face
  • no symptoms of facial flushing, erythema, papules, desquamation, or spot haemorrhage as evaluated by a dermatologist
  • photodamage scores above 2 (evaluated by a dermatologist)
  • compliance with split-face use of the assigned formulations for 56 days
  • no antibiotics remedy in the past three months
  • regular use of sunscreen products at least five times a week
  • no plans to leave Shanghai during the period of the trial
  • compliance with no use of any cosmetics that may bias the study results during the period of the trial
  • written and portrait right consent were obtained from all participants before study entry

Exclusion criteria

Exclusion Criteria:

  • female subjects who are pregnant, lactating or planning to become pregnant
  • history of alcoholism
  • history of allergies
  • subjects who have received medical rejuvenation treatment within the past one year
  • being a participant in any other clinical trial within the past one month
  • subjects who are suffering from facial skin diseases (melasma, acne, and herpes simplex, etc.)
  • subjects with scar constitution or that predispose to Koebner's phenomenon (such as vitiligo and lichen planus, etc.)
  • subjects who had skin diseases (such as psoriasis, eczema, and skin cancer, etc.)
  • taken/injected anti-allergy medication in the past one month
  • subjects who had a high fever in the past 2 weeks
  • received anticancer chemotherapy or immunotherapy in the past 6 months
  • anyone that the investigator thinks of not eligible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Formulation containing MLYAAT-1002® Composition

    After the 1064nm fractional picosecond laser treatment, daily use of the formulation for 56 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.

    Combination Product: Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.

  • Placebo comparator
    Blank formulation without MLYAAT-1002® Composition

    After the 1064nm fractional picosecond laser treatment, daily use of the blank formulation for 56 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.

    Combination Product: Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®

Interventions

  • Combination productFractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.

    Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.

  • Combination productFractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®

    Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.

06

What researchers measure

Primary outcomes

  1. changes in skin manifestations of photodamage (global score)

    Scoring by two independent dermatologists, a global score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  2. changes in skin manifestations of photodamage (tactile skin roughness)

    Scoring by two independent dermatologists, a roughness score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  3. changes in skin manifestations of photodamage (fine lines)

    Scoring by two independent dermatologists, a fine-line score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  4. changes in skin manifestations of photodamage (coarse wrinkles)

    Scoring by two independent dermatologists, a coarse-wrinkle score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  5. changes in skin manifestations of photodamage (mottled pigmentation)

    Scoring by two independent dermatologists, a pigmentation score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  6. changes in skin manifestations of photodamage (erythema)

    Scoring by two independent dermatologists, an erythema score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  7. changes in skin manifestations of photodamage (dull skin)

    Scoring by two independent dermatologists, a dull-skin score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

  8. changes in skin manifestations of photodamage (telangiectasia)

    Scoring by two independent dermatologists, a telangiectasia score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.

    Time frame: Day 0, Day 15, Day 29, Day 57

Secondary outcomes

  1. changes in skin surface hydration(a.u.) of facial skin

    measuring hydration of the stratum corneum by Corneometer® MPA580 (Courage\&Khazaka#Germany)

    Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  2. changes in transepidermal water loss (TEWL#in g/m2/h) of facial skin

    measuring the loss of water that passes from inside a body through the epidermis to the surrounding atmosphere by Tewameter® MPA580 (Courage\&Khazaka#Germany)

    Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  3. changes in index of erythema of facial skin

    measuring erythema by Mexameter MX18(Courage\&Khazaka, Germany)

    Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  4. changes in index of melanin of facial skin

    measuring melanin by Mexameter MX18(Courage\&Khazaka, Germany)

    Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  5. changes in individual typology angle (ITA°) of facial skin

    capturing facial images by VISIA-7 (CANFIELD, America) and calculating the ITA

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  6. changes in the percentage of facial skin pore area

    capturing facial images by VISIA-7 (CANFIELD, America) and calculating the percentage of pore area

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  7. changes in the characteristics of facial wrinkles (depth)

    capturing facial images by VISIA-7 (CANFIELD, America), and recording the depth of wrinkles at the specific face region

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  8. changes in the characteristics of facial wrinkles

    capturing facial images by VISIA-7 (CANFIELD, America), and recording the area of wrinkles at the specific face region

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  9. changes in the characteristics of crow's feet

    capturing facial images by Primos (CANFIELD, America) and calculating the area of crow's feet at the specific face region

    Time frame: Day 0, Day 29, Day 57

  10. safety and tolerability

    Any adverse effects (e.g., erythema, flush, stinging, pruritus, and spot hemorrhage, desquamation) on both sides of face will be recorded at each visit by two independent dermatologists. The severity of the observed effect will be scored on a 5-point scale (0-4) , i.e., higher scores meaning a more severe level .

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

  11. self-assessment by participants

    All the particpants will be asked to report any discomfort (e.g., stinging, pruritus, burning sensation) in their faces at each visit. The severity of the reported discomfort will be scored on a 5-point scale (0-4) , i.e., higher scores meaning a more severe level.

    Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57

07

Study locations

1 site
  • Shanghai China-norm Quality Technical Service Co ,Ltd
    Shanghai, Shanghai 200072, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2024, 2 months.

Of 14 interventional studies with no phase under Skin Manifestations, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Jan 3, 2024
StartActual
Nov 18, 2023
Primary completionActual
Jan 27, 2024
CompletionActual
Aug 15, 2024
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06188338
Lead sponsor
Botanee Group Co., Ltd.
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Nov 18, 2023
Primary completion
Jan 27, 2024
Completion
Aug 15, 2024
Last update
Aug 16, 2024

Study contacts

Yan Shuxian, Dr
principal investigator · Shanghai Yaokang Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion